JPRN-jRCT2080222348未知3 期
A phase 3, randomized, open-label, multi-center clinical study to observe the efficacy and safety of TMX-67 compared to allopurinol in patients with a malignant tumor receiving chemotherapy
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with intermediate or high risk of tumor lysis syndrome (TLS)
排除标准
- •1)Patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS).
- •2)Patients with severe hepatic insufficiency.
- •3)Patients with severe renal insufficiency.
- •4)Performance status of 3 to 4.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate immunogenicity and safety study of GSK Biologicals’ Herpes Zoster (HZ) vaccine GSK1437173A when co-administered with Pneumovax 23 in adults aged 50 years and older.Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults = 50 years of age [YOA ] and immunocompromised adults = 18 YOA.)MedDRA version: 17.0Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-005314-19-EEGlaxoSmithKline Biologicals864
进行中（未招募）
不适用
Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’ seasonal influenza vaccine GSK2321138A in adults aged 50 years and older.Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults = 50 years of age [YOA ] and immunocompromised adults = 18 YOA.)MedDRA version: 17.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000372-15-DEGlaxoSmithKline Biologicals828
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaStaphylococcus aureus Bacteremia Including Infective EndocarditisMedDRA version: 20.0Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862EUCTR2014-004372-27-DETheravance Biopharma Ireland Limited248
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaStaphylococcus aureus Bacteremia Including Infective EndocarditisMedDRA version: 19.1Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862EUCTR2014-004372-27-PLTheravance Biopharma Antibiotics, Inc.248
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and tolerability of telavancin compared with standard intravenous therapy in the treatment of S. aureus bacteremiaStaphylococcus aureus Bacteremia Including Infective EndocarditisMedDRA version: 19.0Level: LLTClassification code 10004035Term: Bacterial infection due to staphylococcus aureusSystem Organ Class: 100000004862EUCTR2014-004372-27-HUTheravance Biopharma Antibiotics, Inc.248